In a filing, Protara Therapeutics Inc revealed its Director Levy Richard S acquired Company’s shares for reported $63800.0 on May 14 ’25. In the deal valued at $3.19 per share,20,000 shares were bought. As a result of this transaction, Levy Richard S now holds 51,000 shares worth roughly $0.25 million.
Then, Zummo Jacqueline sold 21,224 shares, generating $96,145 in total proceeds. Upon selling the shares at $4.53, the Chf Scientific Operations Off now owns 98,861 shares.
Before that, Zummo Jacqueline bought 21,224 shares. Protara Therapeutics Inc shares valued at $96,569 were divested by the Officer at a price of $4.55 per share.
Scotiabank initiated its Protara Therapeutics Inc [TARA] rating to a Sector outperform in a research note published on April 16, 2025; the price target was $12. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. H.C. Wainwright started covering the stock on June 04, 2021. It rated TARA as “a Buy”.
Price Performance Review of TARA
On Friday, Protara Therapeutics Inc [NASDAQ:TARA] saw its stock jump 17.54% to $4.96. Over the last five days, the stock has gained 16.71%. Protara Therapeutics Inc shares have risen nearly 178.65% since the year began. Nevertheless, the stocks have fallen -6.06% over the past one year. While a 52-week high of $10.48 was reached on 01/06/25, a 52-week low of $1.60 was recorded on 07/02/25.
Levels Of Support And Resistance For TARA Stock
The 24-hour chart illustrates a support level at 4.50, which if violated will result in even more drops to 4.05. On the upside, there is a resistance level at 5.22. A further resistance level may holdings at 5.49.
How much short interest is there in Protara Therapeutics Inc?
A steep rise in short interest was recorded in Protara Therapeutics Inc stocks on 2025-09-15, dropping by 81739.0 shares to a total of 2.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 2.77 million shares. There was a decline of -3.04%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 17, 2021 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $43 price target.
